"10.1371_journal.pone.0127549","plos one","2015-05-29T00:00:00Z","Nirit Lev; Yael Barhum; Tali Ben-Zur; Israel Aharony; Lena Trifonov; Noa Regev; Eldad Melamed; Arie Gruzman; Daniel Offen","Felsenstein Medical Research Center, Sackler School of Medicine, Tel-Aviv University, Petach Tikva, Israel; Department of Neurology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel; Division of Medicinal Chemistry, Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan, Israel","Conceived and designed the experiments: NL EM DO. Performed the experiments: NL YB TB IA LT NR. Analyzed the data: NL EM DO. Contributed reagents/materials/analysis tools: AG. Wrote the paper: NL DO.","NL, EM and DO hold patent on ND-13, EM and DO are consultants in Brainstorm Cell Therapeutic. The authors have submitted several patent applications, some of which have already been granted. The inventors are DO, NL and EM; all were assigned to Ramot at Tel Aviv University and licensed to UGH Parma, Inc. Patent name: A method of selecting peptides derived from the DJ-1 protein, certain selected peptides and their use for the treatment of neurodegenerative diseases. and number: 8,378,070; Patent name: Neuroprotective peptides for increasing the viability of cells under oxidative stress conditions and as a result, for the treatment of neurodegenerative diseases. and number:8,212,001; pending patent name:Use of neuroprotective peptides for the treatment of inflammatory diseases. and number:61/889,112; pending patent name: Combination therapy for the treatment of oxidative stress and related disorders and inflammatory diseases and number:61/904,066. We confirm that the patents relating to materials pertinent to this article do not alter our adherence to all PLOS ONE policies on sharing data and materials, as detailed in the guide for authors. All the other authors have nothing to disclose.","2015","05","Nirit Lev","NL",9,TRUE,3,6,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
